Curated News
By: NewsRamp Editorial Staff
June 04, 2025
NanoViricides Advances Measles Treatment with NV-387 Animal Trial
TLDR
- NanoViricides Inc. is advancing NV-387, a potential first-in-class therapeutic for Measles, offering a strategic edge in addressing vaccine failures and rising global cases.
- NV-387, NanoViricides' clinical-stage antiviral, is being tested in genetically modified mice to validate its mechanism of mimicking human cells to neutralize Measles virus.
- NV-387's development by NanoViricides represents hope for combating Measles outbreaks, aiming to improve global health amidst increasing vaccine challenges and declining immunization rates.
- Discover how NanoViricides' NV-387, a drug that cured lethal RSV in animals, is now targeting Measles with a novel approach to virus neutralization.
Impact - Why it Matters
The resurgence of Measles, fueled by vaccine failures and declining immunization rates, poses a significant public health challenge worldwide. NanoViricides' development of NV-387 as a potential therapeutic offers hope in combating this preventable disease, especially in regions where vaccination coverage is inadequate. The success of NV-387 could revolutionize the treatment of Measles and other viral infections, providing a much-needed alternative to traditional vaccines and addressing a critical gap in global health security.
Summary
NanoViricides, Inc. (NYSE American: NNVC) has taken a significant step forward in addressing the global health threat posed by Measles, with the initiation of an animal trial for its clinical-stage antiviral candidate, NV-387. This move comes at a critical time when vaccine failures and declining immunization rates are contributing to a resurgence of the disease. The trial, utilizing genetically modified mice, aims to validate NV-387's potential as the first effective therapeutic for Measles, building on its previous success in curing lethal RSV infections in animals. With Measles cases on the rise in the U.S. and Europe, NanoViricides is positioning NV-387 to meet a critical unmet need in the fight against this preventable disease.
NanoViricides is a pioneer in the development of nanoviricide(TM) class of drug candidates, leveraging proprietary technology from TheraCour Pharma, Inc. The company's lead candidate, NV-387, is being developed as a broad-spectrum antiviral drug targeting a range of infections, including RSV, COVID-19, and influenza. The ongoing efforts to advance NV-387 into Phase II human clinical trials underscore the company's commitment to addressing some of the most pressing viral threats facing the global population today. For more details on this groundbreaking research, visit the full press release.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides Advances Measles Treatment with NV-387 Animal Trial
